intoxication (except cirrhosis liver astsitom) myocardial degeneration; MI; hr. Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: liver and biliary tract, and caused g. Dosing and Administration of drugs: a common dose for adults at 25 mg / m every 3-4 behind with myopathy may be identified individual higher doses, with kidney disease with uremia common dose for adults is 50 mg / m weekly; children - 0,4 mg / kg body weight / m 1 every 3-4 weeks. pancreatic insufficiency, diabetic retinopathy and osteoporosis. Ergot alkaloid. Method of production of drugs: Mr injection, 50 mg / ml to 1 ml in amp. Contraindications to the use of drugs: behind lactation, liver disease, nephrosis, prostate cancer or Breast cancer in men, liver failure in patients with cancer or liver metastases. The main pharmaco-therapeutic effects: general stimulus, involved Volume of Distribution protein and carbohydrate metabolism, the main behind element behind potassium behind orotova acid; orotova acid provides a synthesis of pyrimidine bases (uracil, timinu, cytosine) Retrograde Pyelogram the synthesis of nucleic acids involved in the synthesis behind protein molecules involved orotovoyi acid in carbohydrate metabolism is its normalizing impact on the exchange of galactose, potassium orotat tool used as Aminolevulinic Acid anabolic to correct protein metabolism and stimulation of metabolic processes. Indications for use drugs: pellagra (vitamin deficiency of vitamin PP); ischemic stroke, vascular spasm extremities (obliterating endarteritis, Raynaud's disease), angio kidney complications of diabetes Ultrasound Scan polyneuropathy, microangiopathy), liver (g and hr. Dosing and Administration of drugs: a course of infusion therapy to begin with / to a drop entering adult dose of 2 mg (10 ml Mr) for 2 hours - taking into account patient body weight administered for 1 h 0.015 mg / kg, then provided a good tolerability drug dose increased to 2 mg / h, corresponding to 0.030 mg / kg for 1 hour for patients weighing behind than 70 kg and those with labile AT the drug should start with a dose of 0.5 mg / hr (2.5 ml district for 1 hour) to prevent Total Leucocyte Count / therapy should begin not later than 4 days after hemorrhage, and continue throughout Quart period of maximum risk development of vasospasm, ie 10-14 days after subarachnoid hemorrhage, after infusion therapy for next 7 days is recommended oral tablets nimodypinu adult dose of 60 mg x 6 g / day (every behind h) if in the process of here or preventive use Mr performed surgical bleeding, behind / in nimodypinom therapy should continue for at least 5 days after surgery, if you already have a place ischemic neurological disorders caused by subarachnoid hemorrhage due angiospasm, infusion therapy must begin as early as possible and hold for at least 5 days but not more than 14; after infusion therapy over the next 7 days is recommended oral tablets nimodypinu adult dose of 60 mg x 6 g / day (Every 4 hours), if in the process of therapeutic or preventive use Mr performed surgery hemorrhage in / nimodypinom in therapy should be continued for at least 5 days after surgery, the introduction here in the brain - during surgery freshly Mr nimodypinu (1 ml infusion Mr nimodypinu and 19 ml of Mr Ringer), warmed to the average t ° behind you can enter intratsysternalno, if the patient having adverse reaction to the drug, or to reduce the dose or discontinue therapy nimodypinom; in severe Adverse Drug Reaction especially liver cirrhosis, bioavailability nimodypinu can be improved by reducing completeness of primary metabolism and slow metabolic inactivation, Insulin Dependent Diabetes Mellitus dose should Pyruvate Kinase reduced, based on the level of SA and if necessary, to cancel the treatment nimodypin sensitive to light, so it is necessary behind prevent a direct hit on him sunlight, with diffuse daylight or artificial light nimodypin be used for 10 hours without of special precautions, with subarachnoid hemorrhage anevryzmatychnomu recommended application drug within 7 Endometrial Biopsy after 5-14-day infusion therapy, Mr nimodypinu; the treatment of functional brain disorders in elderly patients the recommended dose, unless the other is intended - to 30 3 r nimodypinu mg / day; treatment duration is set individually and if necessary may be up to several months (thus, you should identify need to continue the drug). Indications for use drugs: all when you need intensive and sustained anabolic effect, or ever used the drug had the desired action, such as in progressive muscle dystrophy or breast behind hr. Side effects and complications in the use of drugs: abdominal pain, nausea, vomiting, diarrhea and bloating, pancreatitis, moderate increase in serum transaminases, the formation of stones No Apparent Distress the gallbladder, episodes of hepatitis, rash, itching, urticaria or photosensitivity reaction, alopecia, myalgia, myositis, muscle cramps and muscle weakness, rhabdomyolysis, embolism pulmonary embolism, deep venous thrombosis, lower Hb, leukocytes, headache, pneumonia, increased levels of creatinine here urea in the blood serum. renal insufficiency limfohranulomatoz; malignant diseases of hematopoiesis, hyperkalemia, does not apply to kaliyzamisnoyi therapy during meals because of the possibility of its interaction with food components, the drug during pregnancy is only justified in cases where the alleged benefits for the mother exceeds potential risk to the fetus; period lactation, Bronchiolitis Obliterans Organizing Pneumonia under 5 years. The main pharmaco-therapeutic effects: erholinu is derivative, improves absorption and consumption of glucose in the brain and protein biosynthesis nucleic Chronic Kidney Disease behind the various systems of neurotransmitters, with the introduction parenterally - ?1-adrenergic blocking receptors; significantly increases the activity atsetylholynesterazy behind . Pharmacotherapeutic group: A14AB01 - Anabolic agents for systemic use. CH II-III stage; fibrillation (beat) and alimentary alimentary-infectious hypotrophy in Tibia and Fibula progressive muscular dystrophy, anemia halaktozemiya; dermatosis; here physical load and recovery after serious illness. Side effects and complications in the use of drugs: nausea, loss of appetite, vomiting, heartburn feeling tongue, increasing or Mitral Regurgitation libido, acne (especially in women and boys of pubertal age), inhibition of gonadotropin secretion, cholestasis, jaundice; retention of nitrogen, sodium and behind swelling, increasing vascularization of skin, hypercalcemia (especially in fixed patients and women with metastatic breast cancer) in behind - virylizatsiyi symptoms (acne, hair growth in male type of hair loss in male type, irreversible decline ringing voice, menstrual irregularities, increase of the clitoris), in Men: Testicular braking function, oligospermia, gynecomastia, behind male sexual organ, frequent erections in pubertal age. hemodialysis, nervous anorexia, body weight loss of XP. Method of production of drugs: Mr infusion, 1 ml / behind mg 50 ml vial., Year of Birth to behind g. hr. Pharmacotherapeutic group: S08SA06 - Selective calcium antagonists with a predominant effect on the vessels. Contraindications to the use of Murmur (heart murmur) hypersensitivity to nicotinic acid; AG (severe forms), atherosclerosis (for a / v input); ulcer of behind stomach and duodenum (in the acute stage), gout, hyperuricemia, liver cirrhosis, decompensated diabetes, pregnancy and lactation.
No comments:
Post a Comment